跳至主要内容
临床试验/2025-523107-30-01
2025-523107-30-01招募中3 期

Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)

Centre Hospitalier Universitaire De Toulouse2 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2026年6月1日最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
76
试验地点
2

研究概览

简要总结

To evaluate, in a group of women who are victims of violence and suffer from PTSD, the effect of treatment consisting of 6 sessions (1 per week) of traumatic memory reactivation under propranolol/PPNL (a single dose of propranolol administered prior to the traumatic memory reactivation) compared to the effect of treatment with 8 sessions (1 per week) of prolonged exposure psychotherapy (EP) on PTSD symptoms.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
性别
Female
接受健康志愿者

入选标准

  • Women aged from 18 to 75 years
  • Having been victim of severe violence (rape, sexual assault, physical assault)
  • Currently suffering from PTSD related to the traumatic event. The diagnosis of PTSD is made according to the DSM-5 criteria by a psychiatrist/psychologist using the CAPS-5, regardless of the traumatic event meeting criterion A of the DSM-5, with or without dissociative symptoms as described in the “With dissociative symptoms” section of the DSM-5, Immediate or delayed PTSD
  • heart rate ≥ 55 bpm
  • The subject must have signed the consent form.
  • The subject must be enrolled in a social security program.
  • The participant must be able to understand and read French.
  • The participant agrees to comply with the contraception requirements outlined in the protocol
  • CAPS-5 total score ≥ 33

排除标准

  • Systolic blood pressure below 100 mm Hg.
  • Patients who have suffered a head injury within the past year or who have clinical symptoms and residual neurological sequelae
  • Wearing contact lenses
  • Hospitalized or treated for suicidal behavior within the past 3 months
  • Previous intolerance to a beta-blocker.
  • Women of childbearing age not using contraception
  • Pregnancy, breastfeeding
  • Current use of a beta-blocker, regardless of the formulation.
  • Known interactions with Propranolol (combination use not recommended and combinations to be used with caution) as indicated in the summary of product characteristics
  • Undergoing psychotherapy or pharmacological treatment with psychotropic agents such as antidepressants, neuroleptics, and/or mood stabilizers. However, these subjects may be included after a 2-week therapeutic abstinence period (6 weeks for treatment with fluoxetine).
  • Patients under judicial protection, under guardianship or curatorship, individuals under family authorization, or under a future protection order with representation regarding the person
  • USevere psychiatric disorders: Severe symptoms of other anxiety disorders, severe symptoms of Obsessive-Compulsive Disorder, history of or current psychotic disorder, bipolar mood disorder, severe personality disorder, alcohol or other substance use disorder
  • Participants who are related to a person involved in the study at the investigator’s center, within the clinical research organization (CRO), or at the sponsor
  • Participation in another interventional research study, clinical trial, or clinical investigation within the 6 months preceding selection
  • “Yes” response to item 4 of the C-SSRS: active suicidal ideation with intent to act, without a specific plan, and/or “Yes” response to item 5 of the C-SSRS: active suicidal ideation with a specific plan and intent to act
  • Propanolol contrindications
  • Heart failure (compensated or decompensated)
  • Severe liver disease
  • Significant renal impairment
  • Myasthenia gravis
  • Personal or family history of psoriasis

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Pr Philippe BIRMES

Scientific

Centre Hospitalier Universitaire De Toulouse

研究点 (2)

Loading locations...

相似试验

Women victims of violences : PTSD treatment by... | 临床试验